Open AccessSafety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies
Author(s) -
Andrew Blauvelt,
Bruce Strober,
Ross Langley,
Daniel Burge,
Lisa Pisenti,
Mohamed Yassine,
Sarah Kavanagh,
Catherine Arendt,
Robert Rolleri,
Kristian Reich
Publication year - 2018
Publication title -
skin
Language(s) - English
Resource type - Journals
ISSN - 2574-1624
DOI - 10.25251/skin.2.supp.16
Subject(s) - certolizumab pegol , placebo , medicine , plaque psoriasis , psoriasis , randomized controlled trial , dermatology , adalimumab , pathology , alternative medicine , tumor necrosis factor alpha
not available. Disclosures: Study sponsored by UCB Pharma. Copyright 2018 SKIN